Imexpharm Corporation (IMP) Fair Value & Analysis
Healthcare · VN · Market cap 6.0T VND
Fair value as of: Jul 19, 2026
From 26 valuation models · updated 22 days ago
Share price −9.2% over the past month.
A solid business, screening 14% undervalued on our models.
What matters now
- The model range is unusually wide (20,809 VND to 56,675 VND). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Our model range runs from 20,809 VND (bear) to 56,675 VND (bull), base 41,910 VND. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 58/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
60‑month range 18,349 VND – 55,874 VND · fair‑value band 20,809 VND – 56,675 VND · the 36,850 VND price screens below the 41,910 VND fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.
Analysis
Imexpharm Corporation (IMP) currently trades at 36,850 VND, while our model-based Fair Value estimate is 41,910 VND, implying the stock looks roughly 13.7% undervalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Imexpharm Corporation generated revenue of 2.4T VND at a net margin of 14.9%. Revenue declined 8.1% year over year. It earns a return on equity of 15.4%. Net debt stands at 23.6B VND. Fundamentals as of Jul 19, 2026
Our scenario range runs from 20,809 VND (bear case) to 56,675 VND (bull case); at 36,850 VND, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 35% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 14%, IMP screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (42,295 VND) versus Growth DCF (4,964 VND). Highest evidence: Growth DCF (80).
Notify me when IMP reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 32
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company's products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, …
Full company description
Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company's products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and minerals, and supplements. It is also involved in the import and export. Imexpharm Corporation was founded in 1997 and is headquartered in Cao Lanh, Vietnam. As of April 29, 2026, Imexpharm Corporation operates as a subsidiary of Livzon Pharmaceutical Group Inc..
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Imexpharm Corporation reported revenue of 2.4T VND in FY2025 versus 1.3T VND in FY2021, a compound +17.8%/yr. Reported net income was 349B VND in FY2025, compounding +16.6%/yr from FY2021.
Watch IMP: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 624 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Imexpharm Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Imexpharm Corporation (IMP) overvalued or undervalued?
What is the fair value of IMP?
What is the quality score of IMP?
What is the revenue of Imexpharm Corporation (IMP)?
What is the net profit margin of IMP?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Imexpharm Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.